P887: IN-HOUSE ANTI BCMA CAR-T THERAPY FOR THE TREATMENT OF RELAPSED REFRACTORY MULTIPLE MYELOMA: PHASE 1 RESULTS.

Gelijkaardige items

• Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial
  door: Nathalie Asherie, et al.
  Gepubliceerd in: (2022-10-01)
• Preclinical evaluation and structural optimization of anti-BCMA CAR to target multiple myeloma
  door: Ortal Harush, et al.
  Gepubliceerd in: (2022-03-01)
• BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma
  door: Yuhan Yan, et al.
  Gepubliceerd in: (2024-11-01)
• Serial treatment of relapsed/refractory multiple myeloma with different BCMA-targeting therapies
  door: Adam D. Cohen, et al.
  Gepubliceerd in: (2019-08-01)
• The Gaining Momentum of BCMA-Directed Therapies for Relapsed/Refractory Multiple Myeloma
  door: Adrian Schmidt
  Gepubliceerd in: (2023-10-01)